The Thyroid Cancer Diagnostics Market size was estimated at USD 2.94 billion in 2023 and is expected to reach USD 4.81 billion by 2032 with a growing CAGR of 5.65% during the forecast period of 2024-2032. This Report underscores the increasing incidence and prevalence of thyroid cancer, as well as regional differences in trends in diagnostic procedures and uptake of newer diagnostic technologies. The research analyzes healthcare expenditure on thyroid cancer diagnostics, evaluating how regions invest in early detection and treatment. It also investigates regulatory trends and approvals, which are pivotal in influencing market dynamics and ensuring the safety and efficacy of diagnostic equipment. The report also explores current research and development, highlighting the innovations contributing to better diagnostic accuracy and enhanced patient outcomes.
Market Dynamics
Drivers
The increasing prevalence of thyroid cancer, particularly papillary carcinoma, is a major driver of the thyroid cancer diagnostics market.
The increasing prevalence of thyroid cancer is a major driving force for technological advancements in diagnostics. The American Cancer Society reported that in 2023, about 44,000 new cases of thyroid cancer were diagnosed in the U.S., which highlights the importance of early detection and accurate diagnostic tools. With the growing trend of papillary and medullary thyroid carcinoma, medical professionals are moving towards more sophisticated molecular testing techniques to enhance diagnostic efficacy and patient care.
Next-generation sequencing (NGS) has proven to be an important tool, as it provides exhaustive genetic profiling of thyroid tumors to recognize mutations like BRAF, RET, and RAS, which are significant in the determination of targeted therapies. Liquid biopsy is also increasingly used as a less invasive substitute for conventional tissue biopsy, facilitating the detection of circulating tumor DNA (ctDNA) in the blood at an early stage. Additionally, the use of artificial intelligence (AI) in imaging diagnostics has greatly improved ultrasound and PET-CT scan precision, minimizing false positives and allowing disease stratification to be improved. Support from regulators is also firming up the market, as with the FDA's selpercatinib (Retevmo) approval for RET-mutant medullary thyroid cancer, a move towards precision medicine and biomarker-based treatments. These innovations, together, have led to improved survival rates and better clinical decision-making, thereby reinforcing the importance of technological advancements in thyroid cancer diagnostics.
Restraints
High Diagnostic Costs and Limited Access in Low-Income Regions
The expense of molecular and genetic testing is still a significant impediment to the universal use of sophisticated thyroid cancer diagnostics. Next-generation sequencing (NGS) tests, which are essential for identifying genetic mutations like BRAF, RET, and RAS, can cost between USD 1,000 and USD 5,000 per test, which is economically prohibitive for most patients, especially in middle- and low-income nations. The exorbitant prices are due to high-tech equipment, specialized skills, and time-consuming procedures, thus making it available only to highly funded healthcare centers.
In addition, inconsistent or unsatisfactory reimbursement policies in different regions complicate the affordability of these tests for patients. Most insurance companies do not cover biomarker-based and molecular diagnostics in full, requiring patients to pay out-of-pocket. Moreover, the lengthy and complicated regulatory approval process for new diagnostic technologies also delays their introduction into the market. All these factors combined prevent the adoption of advanced thyroid cancer diagnostic solutions, limiting timely and precise disease diagnosis.
Opportunities
Expansion of AI and Personalized Medicine in Thyroid Cancer Diagnosis
The convergence of artificial intelligence (AI) into diagnostic imaging and the increased emphasis on personalized medicine open up rich prospects for industry participants. AI-enabled solutions, such as deep-learning algorithms used for ultrasound image analysis, are enhancing early detection and minimizing false positives. The expansion of targeted therapies, such as BRAF and RET inhibitors, is stimulating the demand for companion diagnostics to enable the identification of qualified patients for targeted treatments. Further, growing investment in R&D on non-invasive testing technologies like liquid biopsy will be expected to open new growth opportunities for the market.
Challenges
Stringent regulatory approval processes and varying compliance standards across different countries pose challenges for new diagnostic technologies.
The process of regulatory approval for molecular diagnostic tests and imaging equipment is extremely stringent, involving large-scale clinical verification, safety testing, and conformity to regional standards including FDA (U.S.) and CE (Europe). This results in a substantial lag time in market introduction, hindering the uptake of new diagnostic technologies. Large-scale clinical studies have to be carried out by companies to establish the validity and reliability of new technology, a process that takes years before obtaining approval.
Furthermore, the worldwide shortage of trained professionals, such as pathologists, radiologists, and molecular oncologists, is an increasing issue. Proper diagnosis of thyroid cancer involves proficiency in biopsy analysis, genetic testing, and imaging interpretation, but most developing countries lack specialized staff. This shortage results in increased diagnostic turnaround times, misdiagnosis, and delayed treatments, ultimately impacting patient outcomes. These issues need to be addressed through investments in workforce training, regulatory simplification, and enhanced access to advanced diagnostics globally.
By Type
Papillary carcinoma held the highest market share of 89.2% in 2023 and is the most common type of thyroid cancer. Its high market share is largely due to its high incidence rate, which constitutes almost 80–85% of all thyroid cancers globally. Moreover, improved diagnostic methods, such as ultrasound imaging, fine-needle aspiration biopsy (FNAB), and molecular testing, have greatly enhanced early detection and treatment planning for papillary carcinoma.
The follicular carcinoma segment is likely to expand at the highest rate over the forecast period as awareness increases and molecular diagnostic technology advances. Although less prevalent than papillary carcinoma, thyroid cancer of follicular type tends to necessitate supplementary diagnostic studies like genetic analysis and imaging for detecting metastases, driving demand for more advanced diagnostic methods.
By Technique
The imaging segment captured the highest market share of 37.8% in 2023, mainly because it plays a crucial role in the detection of thyroid nodules and evaluation of cancer development. Diagnostic and monitoring methods like ultrasound, CT scans, MRI, and PET scans are commonly used and provide non-invasive and highly precise results. The growing use of AI-based imaging analysis and enhanced imaging resolution have also driven the segment's growth.
Biopsy, especially fine-needle aspiration biopsy (FNAB), should be the fastest-growing segment based on its vital role in final cancer diagnosis. With the rising use of molecular and genetic analysis in thyroid cancer diagnosis, biopsy procedures are also increasingly using next-generation sequencing (NGS) and biomarker analysis to support individualized treatment plans.
By End-use
Hospital labs held 40.6% of the market share in 2023 due to the large number of diagnostic tests performed in hospitals. Hospitals are still the main site of care for thyroid cancer diagnosis, providing extensive testing services, such as blood tests, imaging, and biopsy procedures. Hospital-associated laboratories also enjoy superior infrastructure, access to experienced professionals, and quick adoption of new diagnostic technologies.
The research institutes segment will grow the fastest because of the growing investment in cancer biomarker discovery, molecular diagnostics, and research into personalized medicine. The ongoing clinical trials on non-invasive diagnostic methods, artificial intelligence-based pathology analysis, and new blood-based screening technologies will be expected to fuel market growth in this segment.
Regional Analysis
The North American region led the thyroid cancer diagnostics market in 2023 due to the high prevalence of the disease, sophisticated healthcare infrastructure, and rising use of molecular diagnostics. The United States is at the forefront with high investments in genetic testing, AI-based imaging, and biomarker studies, in addition to favorable reimbursement policies that increase diagnostic reach. Canada follows, with support from government-funded screening programs and advancements in technology for detecting thyroid cancer.
The Asia-Pacific market is likely to experience the most rapid growth, driven by the increasing incidence of thyroid cancer, growing healthcare spending, and the expanding diagnostic infrastructure in nations such as China, India, and Japan. The adoption is being driven by government efforts to enhance cancer diagnostics and the increasing role of major market players, while advances in imaging and molecular diagnostics are also accelerating market growth.
Abbott Laboratories: Thyroid Function Tests
F. Hoffmann-La Roche Ltd.: Cobas Series
Thermo Fisher Scientific, Inc.: Oncomine Dx Target Test
Siemens Healthineers: Thyroid Cancer Assays
Bio-Rad Laboratories, Inc.: Thyroid-stimulating hormone (TSH) Assays
General Electric (GE Healthcare): Ultrasound Imaging Systems
Koninklijke Philips N.V.: Ultrasound Machines
Toshiba Corporation: Ultrasound Systems
Agilent Technologies, Inc.: Liquid Biopsy Kits
Illumina, Inc.: Next-Generation Sequencing (NGS) Platforms
Eli Lilly and Company: Diagnostic Agents
Canon Inc.: Medical Imaging Equipment
Danaher Corporation: Diagnostic Solutions
Esaote SPA: Ultrasound Equipment
Hologic, Inc.: Diagnostic Products
PerkinElmer, Inc.: Diagnostic Assays
Veracyte, Inc.: Afirma Xpression Atlas
Recent Developments
In Sep 2024, The FDA granted full approval for selpercatinib (Retevmo) for advanced or metastatic RET-mutant medullary thyroid cancer in patients aged 2 years and older requiring systemic therapy. This approval follows the confirmation of RET mutations through an FDA-approved diagnostic test.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 2.94 billion |
| Market Size by 2032 | USD 4.81 billion |
| CAGR | CAGR of 5.65% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type [Papillary Carcinoma, Follicular Carcinoma, Others] • By Technique [Blood Test, Imaging, Biopsy, Others] • By End-use [Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Siemens Healthineers, Bio-Rad Laboratories, Inc., General Electric (GE Healthcare), Koninklijke Philips N.V., Toshiba Corporation, Agilent Technologies, Inc., Illumina, Inc., Eli Lilly and Company, Canon Inc., Danaher Corporation, Esaote S.p.A., Hologic, Inc., PerkinElmer, Inc., Veracyte, Inc. |
Ans: The market is expected to grow at a compound annual growth rate (CAGR) of 5.65% during the forecast period.
Ans: The Thyroid Cancer Diagnostics market is predicted to reach a valuation of USD 2.94 billion by 2032, increasing from USD 4.81 billion in 2023.
Ans: The increasing prevalence of thyroid cancer, particularly papillary carcinoma, is a major driver of the thyroid cancer diagnostics market.
Ans: The expense of molecular and genetic testing is still a significant impediment to the universal use of sophisticated thyroid cancer diagnostics.
Ans: North America dominates the Thyroid Cancer Diagnostics market.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Thyroid Cancer (2023-2032)
5.2 Diagnostic Procedure Trends (2023), by Region
5.3 Adoption of Advanced Diagnostic Technologies (2020-2032), by Region
5.4 Healthcare Spending on Thyroid Cancer Diagnostics, by Region (2023)
5.5 Regulatory Trends and Approvals (2023-2032)
5.6 Research & Development Trends in Thyroid Cancer Diagnostics
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Thyroid Cancer Diagnostics Market Segmentation, by Type
7.1 Chapter Overview
7.2 Papillary Carcinoma
7.2.1 Papillary Carcinoma Market Trends Analysis (2020-2032)
7.2.2 Papillary Carcinoma Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Follicular Carcinoma
7.3.1 Follicular Carcinoma Market Trends Analysis (2020-2032)
7.3.2 Follicular Carcinoma Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Others
7.4.1 Others Market Trends Analysis (2020-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Thyroid Cancer Diagnostics Market Segmentation, by Technique
8.1 Chapter Overview
8.2 Blood Test
8.2.1 Blood Test Market Trends Analysis (2020-2032)
8.2.2 Blood Test Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Imaging
8.3.1 Imaging Market Trends Analysis (2020-2032)
8.3.2 Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Biopsy
8.4.1 Biopsy Market Trends Analysis (2020-2032)
8.4.2 Biopsy Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Thyroid Cancer Diagnostics Market Segmentation, by End-use
9.1 Chapter Overview
9.2 Hospital Laboratories
9.2.1 Hospital Laboratories Market Trends Analysis (2020-2032)
9.2.2 Hospital Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Cancer Diagnostic Centers
9.3.1 Cancer Diagnostic Centers Market Trends Analysis (2020-2032)
9.3.2 Cancer Diagnostic Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Research Institutes
9.4.1 Research Institutes Market Trends Analysis (2020-2032)
9.4.2 Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Others
9.5.1 Others Market Trends Analysis (2020-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.4 North America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.2.5 North America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.6.2 USA Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.2.6.3 USA Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.7.2 Canada Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.2.7.3 Canada Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.8.2 Mexico Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.2.8.3 Mexico Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.1.6.3 Poland Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.1.7.3 Romania Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.1.9 turkey
10.3.1.9.1 Turkey Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.5 Western Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.6.3 Germany Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.7.2 France Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.7.3 France Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.8.2 UK Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.8.3 UK Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.9.3 Italy Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.10.3 Spain Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.13.3 Austria Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.5 Asia Pacific Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.6.2 China Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.6.3 China Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.7.2 India Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.7.3 India Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.8.2 Japan Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.8.3 Japan Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.9.2 South Korea Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.9.3 South Korea Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.10.3 Vietnam Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.11.2 Singapore Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.11.3 Singapore Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.12.2 Australia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.12.3 Australia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.4 Middle East Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.1.5 Middle East Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.1.6.3 UAE Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.4 Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.2.5 Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.4 Latin America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.6.5 Latin America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.6.2 Brazil Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.6.6.3 Brazil Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.7.2 Argentina Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.6.7.3 Argentina Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.8.2 Colombia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.6.8.3 Colombia Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by Technique (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Thyroid Cancer Diagnostics Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Thermo Fisher Scientific, Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Siemens Healthineers AG
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 Bio-Rad Laboratories, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 General Electric (GE Healthcare)
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Koninklijke Philips N.V.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 Toshiba Corporation
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 Agilent Technologies, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Eli Lilly and Company
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Type
Papillary Carcinoma
Follicular Carcinoma
Others
By Technique
Blood Test
Imaging
Biopsy
Others
By End-use
Hospital Laboratories
Cancer Diagnostic Centers
Research Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The IoT Medical Devices Market Size was valued at USD 41.4 billion in 2023 and is expected to reach USD 503.6 billion by 2032 and grow at a CAGR of 32.0% over the forecast period 2024-2032.
The Life Science Analytics Market Size was USD 9.89 Bn in 2023 and is expected to reach at USD 20.0 Bn by 2032, and develop at a CAGR of 7.61% by 2024-2032
The Generative AI in Healthcare Market size was valued at US$ 1.7 Bn in 2023 and is estimated to US$ 19.99 Bn by 2032 with a growing CAGR of 31.5% Over the Forecast Period of 2024-2032.
Postpartum Products Market Size was valued at USD 2.53 billion in 2023 and is expected to reach USD 4.47 billion by 2032, growing at a CAGR of 6.54% over the forecast period 2024-2032.
Healthcare Claims Management Market was valued at USD 15.01 Bn in 2023 and is expected to reach USD 24.93 Bn by 2032, growing at a CAGR of 5.85% from 2024-2032.
The Infusion Pump Rental Market Size was valued at USD 379.65 Million in 2023, and is expected to reach USD 567.32 Million by 2032, and grow at a CAGR of 5.03%.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
